CD19 and hematologic disorder: Hematologic malignancy patients with B lymphocytopenia after anti‐CD20 monoclonal antibody or anti‐CD19 chimeric antigen receptor (CAR) T cell therapy often face prolonged SARS‐CoV‐2 positivity on pharyngeal swabs and persistent or recurrent COVID‐19 infection, resulting in high mortality.